EVANTICA research team is dedicated to engineering mesenchymal stem cell-derived extracellular vesicles (EVs) to enhance their specificity and amplification efficiency, offering a groundbreaking new approach for cancer therapy. The new collaborative project, jointly led by Dr. Minh LE, Assistant Professor at the National University of Singapore, and Professor Yun Han LOH from the Institute of Molecular and Cell Biology (IMCB) at the Agency for Science, Technology and Research (A*STAR) in Singapore, aims to develop an innovative cancer therapy platform technology based on mesenchymal stem cell exosomes.

In this partnership, the scientific team will utilize Applitech's proprietary bioreactors and InnoCellular's specialized culture media for mesenchymal stem cells (MSCs) to scale up MSC amplification for exosome harvesting. Prior to this collaboration, Applitech and InnoCellular have already established a strategic technical cooperation, conducting multiple MSC amplification experiments using Applitech's bioreactors combined with InnoCellular's culture media. The data demonstrates that the MSC amplification efficiency is at least twice that of traditional culture media, highlighting the exceptional performance of their respective products.

It is noteworthy that Applitech's bioreactors, known for their high-quality manufacturing and precise cell culture control systems, provide a stable and reliable cultivation environment for MSC growth, forming the foundation for successful experiments. Furthermore, InnoCellular will closely collaborate with EVANTICA to develop a new pharmaceutical-grade culture media formulation specifically tailored for harvesting exosomes.

The collaboration among Applitech, InnoCellular, and EVANTICA signifies a significant advancement in the field of novel cancer treatments. Through Applitech's outstanding technical support, InnoCellular's advanced specialized culture media formulations, and EVANTICA's pioneering research, the three parties aim to jointly introduce the next generation of highly efficient targeted cancer therapies, offering patients cutting-edge treatment options.

Applitech's independently developed AbioBundle M series glass bioreactors feature m-Control embedded + industrial control unit, classic mini design, compact size, space-saving capability, multi-parallel control, supporting glass jars from 250ml/500ml/1/2/3L, and configurable to support up to 15L glass jars as needed.

InnoCellular's MesenPlifyTM sXF is a completely xenogeneic-free, serum-free human mesenchymal stem cell (MSC) expansion medium optimized for MSC expansion culture. It offers improved consistency and cell proliferation efficiency. The MSCs cultured with it express surface markers compliant with ISCT standards at high levels and retain multi-lineage differentiation potential into chondrocytes, osteocytes, and adipocytes.

About Applitech

Applitech Biological Technology Co., Ltd. as a high-tech enterprise integrating design, R & D, production, sales and service, we are committed to providing professional production and analysis equipment, disposable consumables and overall solutions for the biopharmaceutical field. Since its establishment, we have always been customer-centric,"quality-oriented, service-oriented" as the business policy, based on the optimization, scale-up and production of biotechnology, constantly improving the product line in the field of biopharmaceutical, providing users with all-round professional solutions for biotechnology, and helping users to make new breakthroughs in the field of biopharmaceutical.

Applitech has been deeply engaged in the field of bioreactor for nearly 20 years, and is determined to build high-end independent bioreactor. Our bioreactors cover R & D, pilot scale and cGMP production, and are widely used in the R & D and production of antibodies, vaccines, cell therapy, gene therapy and stem cell therapy. With bioreactor as the core business, we have gradually formed a product layout covering process detection, spectral analysis, cell analysis, online sampling, sample treatment, etc., providing a wide range of products and technical services for domestic and foreign biopharmaceutical enterprises.

The sales and after-sales service network of Applitech covers the whole country, with its headquarters in Guangzhou, branches and product exhibition and application centers in Shanghai and Beijing, offices in Chengdu and Xi'an, and service points in Tianjin, Suzhou, Hangzhou, Wuhan, Nanjing, Lanzhou, Changchun, Qingdao, etc. Ibetel adheres to the service tenet of "professional technology, considerate service and quick action," is customer-oriented, and works closely with technical partners to jointly escort the development of China's biopharmaceutical industry!

About InnoCellular

As a forefront promoter of cell therapy technology, InnoCellular Tech Pte Ltd specializes in developing efficient and cost-effective cell culture media for stem cell and specific cell applications. InnoCellular excels in formulating high-performance, consistent, and high-quality biological products, crucial for advancing the next generation of cell therapies. The company's services encompass a wide range, offering multiple options from basic to specialized formulations tailored to meet specific experimental or clinical research needs.

About EVANTICA

EVANTICA (Engineered Extracellular Vesicles for Anti-Cancer Therapy) is led by Assistant Professor Dr. Minh LE from the National University of Singapore and Professor Yun Han LOH from the Institute of Molecular and Cell Biology (IMCB) at the Agency for Science, Technology and Research (A*STAR). The team includes scientists, clinical doctors, and industrial partners with expertise in drug delivery, stem cell engineering, biomaterials engineering, cancer biology, pharmacology, and clinical trials.